Final  ||| S:0 E:6 ||| JJ
report  ||| S:6 E:13 ||| NN
on  ||| S:13 E:16 ||| IN
the  ||| S:16 E:20 ||| DT
safety  ||| S:20 E:27 ||| NN
assessment  ||| S:27 E:38 ||| NN
of  ||| S:38 E:41 ||| IN
Piper  ||| S:41 E:47 ||| NNP
methysticum  ||| S:47 E:59 ||| FW
leaf ||| S:59 E:63 ||| FW
/ ||| S:63 E:64 ||| FW
root ||| S:64 E:68 ||| FW
/ ||| S:68 E:69 ||| FW
stem  ||| S:69 E:74 ||| FW
extract  ||| S:74 E:82 ||| FW
and  ||| S:82 E:86 ||| CC
Piper  ||| S:86 E:92 ||| NNP
methysticum  ||| S:92 E:104 ||| FW
root  ||| S:104 E:109 ||| FW
extract  ||| S:109 E:117 ||| FW
Piper  ||| S:117 E:123 ||| FW
methysticum  ||| S:123 E:135 ||| FW
leaf ||| S:135 E:139 ||| FW
/ ||| S:139 E:140 ||| FW
root ||| S:140 E:144 ||| FW
/ ||| S:144 E:145 ||| FW
stem  ||| S:145 E:150 ||| FW
extract  ||| S:150 E:158 ||| FW
is  ||| S:158 E:161 ||| VBZ
the  ||| S:161 E:165 ||| DT
cosmetic  ||| S:165 E:174 ||| JJ
ingredient  ||| S:174 E:185 ||| NN
name  ||| S:185 E:190 ||| NN
for  ||| S:190 E:194 ||| IN
a  ||| S:194 E:196 ||| DT
material  ||| S:196 E:205 ||| NN
derived  ||| S:205 E:213 ||| VBN
from  ||| S:213 E:218 ||| IN
the  ||| S:218 E:222 ||| DT
leaves ||| S:222 E:228 ||| NNS
,  ||| S:228 E:230 ||| ,
roots ||| S:230 E:235 ||| NNS
,  ||| S:235 E:237 ||| ,
and  ||| S:237 E:241 ||| CC
stems  ||| S:241 E:247 ||| VBZ
of  ||| S:247 E:250 ||| IN
the  ||| S:250 E:254 ||| DT
Piper  ||| S:254 E:260 ||| NNP
methysticum  ||| S:260 E:272 ||| VBD
G.  ||| S:272 E:275 ||| NNP
Forster  ||| S:275 E:283 ||| NNP
plant ||| S:283 E:288 ||| NN
,  ||| S:288 E:290 ||| ,
commonly  ||| S:290 E:299 ||| RB
known  ||| S:299 E:305 ||| VBN
as  ||| S:305 E:308 ||| IN
kava  ||| S:308 E:313 ||| JJ
kava ||| S:313 E:317 ||| NN
.  ||| S:317 E:319 ||| .
This  ||| S:319 E:324 ||| DT
and  ||| S:324 E:328 ||| CC
other  ||| S:328 E:334 ||| JJ
kava-derived  ||| S:334 E:347 ||| JJ
ingredients  ||| S:347 E:359 ||| NNS
are  ||| S:359 E:363 ||| VBP
used  ||| S:363 E:368 ||| VBN
as  ||| S:368 E:371 ||| IN
skin-conditioning  ||| S:371 E:389 ||| JJ
agents  ||| S:389 E:396 ||| NNS
at  ||| S:396 E:399 ||| IN
concentrations  ||| S:399 E:414 ||| NNS
from  ||| S:414 E:419 ||| IN
0.0001 ||| S:419 E:425 ||| CD
%  ||| S:425 E:427 ||| NN
to  ||| S:427 E:430 ||| TO
0.1 ||| S:430 E:433 ||| CD
% ||| S:433 E:434 ||| NN
.  ||| S:434 E:436 ||| .
The  ||| S:436 E:440 ||| DT
Food  ||| S:440 E:445 ||| NNP
and  ||| S:445 E:449 ||| CC
Drug  ||| S:449 E:454 ||| NNP
Administration  ||| S:454 E:469 ||| NNP
issued  ||| S:469 E:476 ||| VBD
a  ||| S:476 E:478 ||| DT
consumer  ||| S:478 E:487 ||| NN
advisory  ||| S:487 E:496 ||| NN
in  ||| S:496 E:499 ||| IN
2002  ||| S:499 E:504 ||| CD
expressing  ||| S:504 E:515 ||| JJ
concern  ||| S:515 E:523 ||| NN
about  ||| S:523 E:529 ||| IN
liver  ||| S:529 E:535 ||| JJ
damage  ||| S:535 E:542 ||| NN
in  ||| S:542 E:545 ||| IN
individuals  ||| S:545 E:557 ||| NNS
who  ||| S:557 E:561 ||| WP
have  ||| S:561 E:566 ||| VBP
ingested  ||| S:566 E:575 ||| JJ
kava  ||| S:575 E:580 ||| JJ
products ||| S:580 E:588 ||| NNS
.  ||| S:588 E:590 ||| .
The  ||| S:590 E:594 ||| DT
available  ||| S:594 E:604 ||| JJ
oral  ||| S:604 E:609 ||| JJ
toxicity  ||| S:609 E:618 ||| NN
data  ||| S:618 E:623 ||| NNS
support  ||| S:623 E:631 ||| VBP
the  ||| S:631 E:635 ||| DT
concern  ||| S:635 E:643 ||| NN
about  ||| S:643 E:649 ||| IN
liver  ||| S:649 E:655 ||| JJ
damage  ||| S:655 E:662 ||| NN
on  ||| S:662 E:665 ||| IN
ingestion  ||| S:665 E:675 ||| NN
but  ||| S:675 E:679 ||| CC
do  ||| S:679 E:682 ||| VBP
not  ||| S:682 E:686 ||| RB
resolve  ||| S:686 E:694 ||| VB
the  ||| S:694 E:698 ||| DT
question ||| S:698 E:706 ||| NN
,  ||| S:706 E:708 ||| ,
for  ||| S:708 E:712 ||| IN
example ||| S:712 E:719 ||| NN
,  ||| S:719 E:721 ||| ,
whether  ||| S:721 E:729 ||| IN
these  ||| S:729 E:735 ||| DT
ingredients  ||| S:735 E:747 ||| NNS
would  ||| S:747 E:753 ||| MD
be  ||| S:753 E:756 ||| VB
substantially  ||| S:756 E:770 ||| RB
absorbed  ||| S:770 E:779 ||| VBN
through  ||| S:779 E:787 ||| IN
the  ||| S:787 E:791 ||| DT
skin ||| S:791 E:795 ||| NN
.  ||| S:795 E:797 ||| .
Other  ||| S:797 E:803 ||| JJ
data  ||| S:803 E:808 ||| NN
needs  ||| S:808 E:814 ||| NNS
are  ||| S:814 E:818 ||| VBP
described ||| S:818 E:827 ||| VBN
,  ||| S:827 E:829 ||| ,
including  ||| S:829 E:839 ||| VBG
toxicology  ||| S:839 E:850 ||| JJ
data  ||| S:850 E:855 ||| NNS
for  ||| S:855 E:859 ||| IN
yangonin ||| S:859 E:867 ||| NN
,  ||| S:867 E:869 ||| ,
methysticin ||| S:869 E:880 ||| NN
,  ||| S:880 E:882 ||| ,
and  ||| S:882 E:886 ||| CC
kavain ||| S:886 E:892 ||| NN
,  ||| S:892 E:894 ||| ,
which  ||| S:894 E:900 ||| WDT
may  ||| S:900 E:904 ||| MD
be  ||| S:904 E:907 ||| VB
present  ||| S:907 E:915 ||| JJ
in  ||| S:915 E:918 ||| IN
kava-derived  ||| S:918 E:931 ||| JJ
ingredients ||| S:931 E:942 ||| NNS
.  ||| S:942 E:944 ||| .
Accordingly ||| S:944 E:955 ||| RB
,  ||| S:955 E:957 ||| ,
the  ||| S:957 E:961 ||| DT
available  ||| S:961 E:971 ||| JJ
data  ||| S:971 E:976 ||| NNS
are  ||| S:976 E:980 ||| VBP
insufficient  ||| S:980 E:993 ||| JJ
to  ||| S:993 E:996 ||| TO
support  ||| S:996 E:1004 ||| VB
the  ||| S:1004 E:1008 ||| DT
safety  ||| S:1008 E:1015 ||| NN
of  ||| S:1015 E:1018 ||| IN
these  ||| S:1018 E:1024 ||| DT
ingredients  ||| S:1024 E:1036 ||| NNS
in  ||| S:1036 E:1039 ||| IN
cosmetics ||| S:1039 E:1048 ||| NNS
.  ||| S:1048 E:1050 ||| .
